Cargando…
Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation
PURPOSE: To develop an evidence-based clinical practice guideline for the prevention of oral mucositis in children (0–18 years) receiving treatment for cancer or undergoing haematopoietic stem cell transplantation (HSCT). METHODS: The Mucositis Prevention Guideline Development Group was interdiscipl...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339548/ https://www.ncbi.nlm.nih.gov/pubmed/25818385 http://dx.doi.org/10.1136/bmjspcare-2014-000804 |
_version_ | 1782512681282961408 |
---|---|
author | Sung, Lillian Robinson, Paula Treister, Nathaniel Baggott, Tina Gibson, Paul Tissing, Wim Wiernikowski, John Brinklow, Jennifer Dupuis, L Lee |
author_facet | Sung, Lillian Robinson, Paula Treister, Nathaniel Baggott, Tina Gibson, Paul Tissing, Wim Wiernikowski, John Brinklow, Jennifer Dupuis, L Lee |
author_sort | Sung, Lillian |
collection | PubMed |
description | PURPOSE: To develop an evidence-based clinical practice guideline for the prevention of oral mucositis in children (0–18 years) receiving treatment for cancer or undergoing haematopoietic stem cell transplantation (HSCT). METHODS: The Mucositis Prevention Guideline Development Group was interdisciplinary and included internationally recognised experts in paediatric mucositis. For the evidence review, we included randomised controlled trials (RCTs) conducted in either children or adults evaluating the following interventions selected according to prespecified criteria: cryotherapy, low level light therapy (LLLT) and keratinocyte growth factor (KGF). We also examined RCTs of any intervention conducted in children. For all systematic reviews, we synthesised the occurrence of severe oral mucositis. The Grades of Recommendation, Assessment, Development and Evaluation approach was used to describe quality of evidence and strength of recommendations. RESULTS: We suggest cryotherapy or LLLT may be offered to cooperative children receiving chemotherapy or HSCT conditioning with regimens associated with a high rate of mucositis. We also suggest KGF may be offered to children receiving HSCT conditioning with regimens associated with a high rate of severe mucositis. However, KGF use merits caution as there is a lack of efficacy and toxicity data in children, and a lack of long-term follow-up data in paediatric cancers. No other interventions were recommended for oral mucositis prevention in children. CONCLUSIONS: All three specific interventions evaluated in this clinical practice guideline were associated with a weak recommendation for use. There may be important organisational and cost barriers to the adoption of LLLT and KGF. Considerations for implementation and key research gaps are highlighted. |
format | Online Article Text |
id | pubmed-5339548 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-53395482017-03-20 Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation Sung, Lillian Robinson, Paula Treister, Nathaniel Baggott, Tina Gibson, Paul Tissing, Wim Wiernikowski, John Brinklow, Jennifer Dupuis, L Lee BMJ Support Palliat Care Review PURPOSE: To develop an evidence-based clinical practice guideline for the prevention of oral mucositis in children (0–18 years) receiving treatment for cancer or undergoing haematopoietic stem cell transplantation (HSCT). METHODS: The Mucositis Prevention Guideline Development Group was interdisciplinary and included internationally recognised experts in paediatric mucositis. For the evidence review, we included randomised controlled trials (RCTs) conducted in either children or adults evaluating the following interventions selected according to prespecified criteria: cryotherapy, low level light therapy (LLLT) and keratinocyte growth factor (KGF). We also examined RCTs of any intervention conducted in children. For all systematic reviews, we synthesised the occurrence of severe oral mucositis. The Grades of Recommendation, Assessment, Development and Evaluation approach was used to describe quality of evidence and strength of recommendations. RESULTS: We suggest cryotherapy or LLLT may be offered to cooperative children receiving chemotherapy or HSCT conditioning with regimens associated with a high rate of mucositis. We also suggest KGF may be offered to children receiving HSCT conditioning with regimens associated with a high rate of severe mucositis. However, KGF use merits caution as there is a lack of efficacy and toxicity data in children, and a lack of long-term follow-up data in paediatric cancers. No other interventions were recommended for oral mucositis prevention in children. CONCLUSIONS: All three specific interventions evaluated in this clinical practice guideline were associated with a weak recommendation for use. There may be important organisational and cost barriers to the adoption of LLLT and KGF. Considerations for implementation and key research gaps are highlighted. BMJ Publishing Group 2017-03 2015-03-27 /pmc/articles/PMC5339548/ /pubmed/25818385 http://dx.doi.org/10.1136/bmjspcare-2014-000804 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Review Sung, Lillian Robinson, Paula Treister, Nathaniel Baggott, Tina Gibson, Paul Tissing, Wim Wiernikowski, John Brinklow, Jennifer Dupuis, L Lee Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation |
title | Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation |
title_full | Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation |
title_fullStr | Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation |
title_full_unstemmed | Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation |
title_short | Guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation |
title_sort | guideline for the prevention of oral and oropharyngeal mucositis in children receiving treatment for cancer or undergoing haematopoietic stem cell transplantation |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5339548/ https://www.ncbi.nlm.nih.gov/pubmed/25818385 http://dx.doi.org/10.1136/bmjspcare-2014-000804 |
work_keys_str_mv | AT sunglillian guidelineforthepreventionoforalandoropharyngealmucositisinchildrenreceivingtreatmentforcancerorundergoinghaematopoieticstemcelltransplantation AT robinsonpaula guidelineforthepreventionoforalandoropharyngealmucositisinchildrenreceivingtreatmentforcancerorundergoinghaematopoieticstemcelltransplantation AT treisternathaniel guidelineforthepreventionoforalandoropharyngealmucositisinchildrenreceivingtreatmentforcancerorundergoinghaematopoieticstemcelltransplantation AT baggotttina guidelineforthepreventionoforalandoropharyngealmucositisinchildrenreceivingtreatmentforcancerorundergoinghaematopoieticstemcelltransplantation AT gibsonpaul guidelineforthepreventionoforalandoropharyngealmucositisinchildrenreceivingtreatmentforcancerorundergoinghaematopoieticstemcelltransplantation AT tissingwim guidelineforthepreventionoforalandoropharyngealmucositisinchildrenreceivingtreatmentforcancerorundergoinghaematopoieticstemcelltransplantation AT wiernikowskijohn guidelineforthepreventionoforalandoropharyngealmucositisinchildrenreceivingtreatmentforcancerorundergoinghaematopoieticstemcelltransplantation AT brinklowjennifer guidelineforthepreventionoforalandoropharyngealmucositisinchildrenreceivingtreatmentforcancerorundergoinghaematopoieticstemcelltransplantation AT dupuisllee guidelineforthepreventionoforalandoropharyngealmucositisinchildrenreceivingtreatmentforcancerorundergoinghaematopoieticstemcelltransplantation |